Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed the day trading at $42.38 down -1.05% from the previous closing price of $42.83. In other words, the price has decreased by -$1.05 from its previous closing price. On the day, 1.95 million shares were traded. IONS stock price reached its highest trading level at $42.92 during the session, while it also had its lowest trading level at $41.67.
Ratios:
For a better understanding of IONS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.62 and its Current Ratio is at 9.66. In the meantime, Its Debt-to-Equity ratio is 4.12 whereas as Long-Term Debt/Eq ratio is at 4.09.
On April 07, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $45.
On March 31, 2025, Redburn Atlantic started tracking the stock assigning a Neutral rating and target price of $39.Redburn Atlantic initiated its Neutral rating on March 31, 2025, with a $39 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 01 ’25 when Hayden Michael R bought 15,000 shares for $31.86 per share. The transaction valued at 477,900 led to the insider holds 50,219 shares of the business.
Birchler Brian sold 680 shares of IONS for $19,292 on Apr 16 ’25. The EVP, Corp and Development Ops now owns 56,660 shares after completing the transaction at $28.37 per share. On Apr 16 ’25, another insider, Jenne Kyle, who serves as the EVP, Chf GL Pdt Str Ofcr of the company, sold 3,016 shares for $28.36 each. As a result, the insider received 85,534 and left with 11,199 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 6745159168 and an Enterprise Value of 6108697088. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.40 while its Price-to-Book (P/B) ratio in mrq is 14.17. Its current Enterprise Value per Revenue stands at 8.517 whereas that against EBITDA is -13.255.
Stock Price History:
The Beta on a monthly basis for IONS is 0.24, which has changed by -0.11708331 over the last 52 weeks, in comparison to a change of 0.11844492 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $52.34, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 18.56%, while the 200-Day Moving Average is calculated to be 21.62%.
Shares Statistics:
Over the past 3-months, IONS traded about 1.71M shares per day on average, while over the past 10 days, IONS traded about 2239290 shares per day. A total of 159.04M shares are outstanding, with a floating share count of 155.28M. Insiders hold about 2.44% of the company’s shares, while institutions hold 104.18% stake in the company. Shares short for IONS as of 1749772800 were 14225565 with a Short Ratio of 8.34, compared to 1747267200 on 15266156. Therefore, it implies a Short% of Shares Outstanding of 14225565 and a Short% of Float of 11.8599996.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
